Estradiol valerate and estradiol valerate/dienogest (natazia) tablets: the first four-phasic oral contraceptive.
Uche Anadu Ndefo, Nina Mosely
Abstract
Uche Anadu Ndefo, Nina Mosely
Abstract
This article focuses upon the May 2010 FDA approved estradiol valerate and estradiol valerate/dienogest (Natazia) tablets which is the first four-phasic oral contraceptive. It discusses: the indications and usage the clinical pharmacology including mechanism of action and pharmacokinetics clinical trials adverse drug effects drug interactions contraindications warnings dosage and administration and cost.
OpenAlex reports 7 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
This article focuses upon the May 2010 FDA approved estradiol valerate and estradiol valerate/dienogest (Natazia) tablets which is the first four-phasic oral contraceptive. It discusses: the indications and usage the clinical pharmacology including mechanism of action and pharmacokinetics clinical trials adverse drug effects drug interactions contraindications warnings dosage and administration and cost.
Key concepts: Estradiol valerate, Dienogest, Valerate, Medicine, Pharmacology, Clinical trial, Drug, Adverse effect